Bluejay Diagnostics Stock Nearly Triples After U.S. Manufacturing Deal — Here’s the FDA Catch
Bluejay Diagnostics shares surged in late-morning Nasdaq trading on Tuesday after the micro-cap diagnostics company announced a U.S. manufacturing partnership for its Symphony sepsis-testing platform. The stock was up about 171% at $5.88 after touching $8.38, with volume above 61 million shares and market value still only about $5.8 million.